Merck (MRK) closed at $79.17 in the latest trading session, marking a -0.01% move from the prior day. The stock fell short of the S&P 500, which registered a gain of 0.79% for the day. Elsewhere, the ...

The Trump administration carved out an exception for pharmaceuticals from the president's new tariff regime, at least for now ...

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, the US drugmaker’s second recent foray into China for a novel medicine.

(Reuters) -Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, the latest in a series of deals U.S. drugmakers have ...

Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor. In return for the ex-China rights to the drug, dubbed HRS-5346, Merck has ...

It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 7.2% over the past three months. But if you pay close attention, you might gather that ...

Merck was one of the pioneers of the cholesterol-lowering statins that launched in the 1980s and 1990s and changed medical practice. But it hasn’t been as successful with cholesterol medicines since ...

Investing.com -- Moody’s Ratings has upgraded the ratings of pharmaceutical giant Merck & Co (NYSE:MRK)., Inc. and its subsidiaries to Aa3 from A1. The revised ratings apply to Merck & Co., Inc ...

EMD Serono is the North American drug development business of Merck KGaA, Darmstadt, Germany. A couple of months later, the company announced that President Chris Round would retire, and be ...

Dairy farmers across the country are turning to internet-connected “smart” collars, ear and leg tags to track the specific movements and patterns of their cows. The goal is to better manage ...

The stock of Merck MRK has declined 19.2% in the past six months, losing almost $52 billion of its market value The numerous challenges plaguing the company resulted in the dilution of the stock ...